These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 2256811

  • 1. Recovery from vegetative state of six months' duration associated with Sinemet (levodopa/carbidopa).
    Haig AJ, Ruess JM.
    Arch Phys Med Rehabil; 1990 Dec; 71(13):1081-3. PubMed ID: 2256811
    [Abstract] [Full Text] [Related]

  • 2. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM, Hoey M, Kutt H, McDowell FH.
    Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
    [Abstract] [Full Text] [Related]

  • 3. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
    Miyoshi Y, Zhang Z, Ovadia A, Lapchak PA, Collins F, Hilt D, Lebel C, Kryscio R, Gash DM.
    Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
    [Abstract] [Full Text] [Related]

  • 4. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
    Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S.
    Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
    [Abstract] [Full Text] [Related]

  • 5. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J.
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [Abstract] [Full Text] [Related]

  • 6. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
    Aarli JA, Gilhus NE.
    Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
    [Abstract] [Full Text] [Related]

  • 7. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I, Gawel MJ, Riopelle RJ, Bouchard S.
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [Abstract] [Full Text] [Related]

  • 8. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW, Alberts MJ.
    Adv Neurol; 1987 Nov; 45():555-60. PubMed ID: 3548266
    [No Abstract] [Full Text] [Related]

  • 9. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P, Fierro A, Reyes-Parada M, Sáez-Briones P.
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [Abstract] [Full Text] [Related]

  • 10. Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
    Rodnitzky RL, Dickins QS, Dobson J.
    Neurology; 1989 Nov; 39(11 Suppl 2):92-5; discussion 95. PubMed ID: 2586769
    [Abstract] [Full Text] [Related]

  • 11. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R, Lyons K, McGuire D, Silverstein P, Zwiebel F, Robischon M, Koller WC.
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy.
    Simsek T, Eryilmaz T, Acaroglu G.
    Int J Clin Pract; 2005 Mar; 59(3):287-90. PubMed ID: 15857324
    [Abstract] [Full Text] [Related]

  • 13. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA, Pfeiffer RF, Tagliati M, Kastenholz KV, DeRoche C, Slevin JT.
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [Abstract] [Full Text] [Related]

  • 14. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
    Goetz CG, Tanner CM, Gilley DW, Klawans HL.
    Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
    [Abstract] [Full Text] [Related]

  • 15. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
    Cedarbaum JM, Kutt H, McDowell FH.
    Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
    [Abstract] [Full Text] [Related]

  • 16. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
    LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kareti D, Schlick P.
    Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
    [Abstract] [Full Text] [Related]

  • 17. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB, Suchowersky O, Purves S, Calne S, Calne DB.
    Clin Neuropharmacol; 1986 Nov; 9(2):196-9. PubMed ID: 3708604
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
    Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, Smith ME, Titus DC.
    Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
    [Abstract] [Full Text] [Related]

  • 19. Parkinson's disease: Cogentin with Sinemet, a better response.
    Tourtellotte WW, Potvin AR, Syndulko K, Hirsch SB, Gilden ER, Potvin JH, Hansch EC.
    Prog Neuropsychopharmacol Biol Psychiatry; 1982 Nov; 6(1):51-5. PubMed ID: 7202230
    [Abstract] [Full Text] [Related]

  • 20. Levodopa can worsen tremor associated with dystonia.
    Hensman DJ, Bain PG.
    Mov Disord; 2006 Oct; 21(10):1778-80. PubMed ID: 16856131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.